BR112022001070A2 - Composição de imunogenicidade polivalente para papilomavírus humano - Google Patents
Composição de imunogenicidade polivalente para papilomavírus humanoInfo
- Publication number
- BR112022001070A2 BR112022001070A2 BR112022001070A BR112022001070A BR112022001070A2 BR 112022001070 A2 BR112022001070 A2 BR 112022001070A2 BR 112022001070 A BR112022001070 A BR 112022001070A BR 112022001070 A BR112022001070 A BR 112022001070A BR 112022001070 A2 BR112022001070 A2 BR 112022001070A2
- Authority
- BR
- Brazil
- Prior art keywords
- hpv
- human papillomavirus
- polyvalent
- virus
- types
- Prior art date
Links
- 241000701806 Human papillomavirus Species 0.000 title abstract 3
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 239000002245 particle Substances 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
composição de imunogenicidade polivalente para papilomavírus humano. a presente invenção refere-se a uma composição imunogênica de hpv multivalente para impedir doenças ou infecções relacionadas ao papilomavírus humano (hpv) e usos da mesma. a dita composição imunogênica de hpv multivalente compreende: partículas similares ao vírus hpv montadas a partir de proteínas l1 dos tipos de hpv 6, 11, 16, 18, 31, 33, 45, 52 e 58; e uma ou mais partículas similares ao vírus hpv montadas a partir de proteínas l1 de outros tipos de hpv patogênicos. em uma modalidade, o dito um ou mais outros tipos de hpv patogênicos são selecionados dentre os tipos de hpv 35, 39, 51, 56 e 59. em uma modalidade, pelo menos uma das ditas partículas similares ao vírus hpv é uma partícula similar ao vírus hpv quimérica, e a dita partícula similar ao vírus hpv quimérica compreende uma ou mais proteínas l1 de hpv quiméricas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910657255 | 2019-07-19 | ||
| PCT/CN2020/102601 WO2021013071A1 (zh) | 2019-07-19 | 2020-07-17 | 人***瘤病毒多价免疫原性组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022001070A2 true BR112022001070A2 (pt) | 2022-04-19 |
Family
ID=74193232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022001070A BR112022001070A2 (pt) | 2019-07-19 | 2020-07-17 | Composição de imunogenicidade polivalente para papilomavírus humano |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220370590A1 (pt) |
| EP (1) | EP4001298A4 (pt) |
| JP (1) | JP2022540950A (pt) |
| KR (1) | KR20220074855A (pt) |
| CN (1) | CN114127092B (pt) |
| AU (1) | AU2020317321B2 (pt) |
| BR (1) | BR112022001070A2 (pt) |
| CA (1) | CA3147849A1 (pt) |
| MX (1) | MX2022000777A (pt) |
| WO (1) | WO2021013071A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024503452A (ja) * | 2021-01-14 | 2024-01-25 | 神州細胞工程有限公司 | ヒトパピローマウイルスウイルス様粒子ワクチンの安定な調製 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066324A (en) | 1994-10-07 | 2000-05-23 | Loyola University Of Chicago | Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles |
| US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
| US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
| CN101518647A (zh) * | 2008-02-29 | 2009-09-02 | 江阴艾托金生物技术有限公司 | 人***瘤病毒预防性疫苗、构建方法及应用 |
| IN2013CN00536A (pt) * | 2010-07-02 | 2015-07-03 | Univ Xiamen | |
| CN102747047B (zh) * | 2012-02-28 | 2016-03-23 | 厦门大学 | 人***瘤病毒型别杂合病毒样颗粒及其制备方法 |
| CN104120088B (zh) * | 2013-04-26 | 2019-09-24 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达***产生hpv58 l1蛋白的方法 |
| US10413603B2 (en) * | 2014-06-19 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for improved human papilloma virus constructs |
-
2020
- 2020-07-17 BR BR112022001070A patent/BR112022001070A2/pt active Search and Examination
- 2020-07-17 EP EP20843624.6A patent/EP4001298A4/en active Pending
- 2020-07-17 JP JP2022503540A patent/JP2022540950A/ja active Pending
- 2020-07-17 CA CA3147849A patent/CA3147849A1/en active Pending
- 2020-07-17 CN CN202080051322.2A patent/CN114127092B/zh active Active
- 2020-07-17 MX MX2022000777A patent/MX2022000777A/es unknown
- 2020-07-17 AU AU2020317321A patent/AU2020317321B2/en active Active
- 2020-07-17 WO PCT/CN2020/102601 patent/WO2021013071A1/zh unknown
- 2020-07-17 KR KR1020227005633A patent/KR20220074855A/ko unknown
-
2022
- 2022-01-19 US US17/579,459 patent/US20220370590A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4001298A4 (en) | 2023-03-15 |
| CN114127092A (zh) | 2022-03-01 |
| MX2022000777A (es) | 2022-02-14 |
| WO2021013071A1 (zh) | 2021-01-28 |
| AU2020317321B2 (en) | 2023-07-27 |
| US20220370590A1 (en) | 2022-11-24 |
| AU2020317321A1 (en) | 2022-03-10 |
| JP2022540950A (ja) | 2022-09-20 |
| CN114127092B (zh) | 2024-04-16 |
| KR20220074855A (ko) | 2022-06-03 |
| CA3147849A1 (en) | 2021-01-28 |
| EP4001298A1 (en) | 2022-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| BR112022020486A2 (pt) | Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso | |
| DK2343084T3 (da) | Funktionelle influenzavirus-lignende partikler (VLP) | |
| BR112017018022A2 (pt) | "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| WO2016198531A3 (en) | Hpv vaccines | |
| BR112012022688A2 (pt) | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão | |
| BR112015017069A2 (pt) | processo para preparação de extrato a partir de meio de cultura de ceriporialacerata e composições farmacêuticas preparadas pelo que para prevenção ou tratamento de doenças diabéticas e complicações diabéticas, que contêm extrato de meio de cultura de ceriporialacerata como ingrediente ativo | |
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| JP2014530010A5 (pt) | ||
| BR0209837A (pt) | Partìcula semelhante a vìrus isolada ou recombimante capaz de replicação, composição, e, método para inibir ou bloquear uma infecção com um coronavìrus ou partìcula semelhante a coronavìrus | |
| TR201908199T4 (tr) | HPV'ye karşı aşılar. | |
| BR112014015390A8 (pt) | vírus da estomatite vesicular para vacinas iniciais e de reforço | |
| BR112018068342A2 (pt) | vacina de vírus zika vivo atenuado | |
| RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
| BR112015024552A2 (pt) | compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções | |
| BR0312474A (pt) | Partìcula viral adjuvante | |
| BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
| JP2016508999A5 (pt) | ||
| BR112018011310A2 (pt) | mutante da proteína l1 do papilomavírus humano tipo 58 | |
| BR112018011331A2 (pt) | mutante de proteìna l1 de papillomavirus humano tipo 11 | |
| BR112022015313A2 (pt) | Vacina de hpv | |
| BR112022001070A2 (pt) | Composição de imunogenicidade polivalente para papilomavírus humano | |
| WO2020035609A3 (en) | Immunogenic compositions and uses thereof | |
| BR112015031226A2 (pt) | Composição de vacina, e, uso da composição de vacina | |
| BRPI0606165A2 (pt) | método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: VIDE PARECER. |